Funding and Financials - The company has secured approximately $282.5 million in funding from U.S. government contracts since 2013, with $272.9 million from BARDA, and a new contract with BARDA provides up to $150 million in additional funding[24]. - The company executed a new contract with BARDA on September 27, 2023, providing up to $150.0 million in funding, including an initial award of approximately $54.9 million for the clinical validation and FDA clearance of the DeepView System[72]. - The BARDA contract is the largest single source of revenue for the company, with a prior contract option valued at approximately $21.9 million replaced by the new contract[77]. - The company has not made any commercial sales of the DeepView System and relies almost entirely on funding from BARDA and the Defense Health Agency (DHA)[76]. - The company expects its cash and cash equivalents, along with remaining funding from BARDA and other agreements, to be sufficient to meet capital requirements for at least the next 12 months[84]. - The company may require additional funding to finance operations and product development, with no assurances that it will be able to raise capital on favorable terms[85]. - For the year ended December 31, 2025, the company incurred a net loss of $7.5 million, compared to a net loss of $15.1 million for the year ended December 31, 2024, with an accumulated deficit of approximately $55.8 million as of December 31, 2025[71]. Product Development and Technology - The DeepView System's AI algorithm has shown superiority in sensitivity and met the non-inferiority margin for specificity compared to clinician assessments, significantly improving diagnostic accuracy for burn injuries[28][37]. - The proprietary database for burns consists of over 340 billion pixels of image data, creating a substantial barrier to entry for competitors[29]. - The DeepView System can provide a "Day One" assessment of a wound's healing potential, reducing the current time to decision from 21 days to 1 day[40]. - The DeepView System is the only AI-enabled wound imaging technology that provides predictive wound healing assessments, differentiating it from existing systems[51]. - The company is focused on the development of the DeepView System, with potential applications beyond the current burn indication[74]. - The company has acquired over 340 billion pixels of proprietary image data for training deep learning algorithms, creating a significant barrier to entry for competitors in wound care healing assessments[200]. - The company has developed strategic partnerships with multiple clinical and academic partners in the U.S. and Europe to access diverse wound data inputs, which is critical for improving DeepView algorithms[201]. Regulatory and Compliance - The company must receive 510(k) clearance, PMA approval, or De Novo classification to market new medical devices in the U.S., with potential delays and high costs associated with the PMA route[93]. - Compliance with EU Medical Devices Regulation is required to affix the CE mark, which is essential for selling devices in the EU[94]. - The regulatory review process for the DeepView technology is expensive and uncertain, with no guarantee of obtaining necessary approvals or clearances[90]. - The FDA and foreign regulatory entities can delay or deny market authorization for various reasons, affecting revenue generation timelines[98]. - The company relies on third parties for clinical trials, and any failure in their performance could hinder obtaining necessary regulatory approvals[99]. - Ongoing regulatory compliance is required even after obtaining market authorization, with potential enforcement actions for non-compliance[111]. - The company must comply with various healthcare laws, including the Anti-Kickback Statute and the False Claims Act, which could impose significant liabilities if violated[123]. - The company faces significant risks from potential non-compliance with healthcare regulations, which could lead to substantial fines, imprisonment, and exclusion from government healthcare programs[125]. Market Strategy and Competition - The company plans to target approximately 140 burn centers, 700 trauma centers, and 5,400 federal and community hospitals in the U.S. for the deployment of the DeepView System[25]. - The company aims to establish strong relationships with leading U.S. hospitals to promote the DeepView System, leveraging partnerships to increase awareness and adoption[149]. - The commercial success of the DeepView System will depend on market acceptance by clinicians, with risks of slow market development adversely affecting business results[147]. - The company faces significant competition from established manufacturers with greater resources, which may limit market penetration[161]. - If third-party payors do not provide adequate coverage and reimbursement for the DeepView System, it could negatively impact sales and business prospects[156]. - The pricing and margins for the DeepView System may be pressured by reimbursement rates and competition, affecting revenue and growth potential[159]. Operational Challenges - The company anticipates significant growth in operations, particularly in manufacturing and sales, which may strain management and operational resources[179]. - The company relies on third-party manufacturers, exposing it to risks related to product quality and compliance with regulatory standards, which could disrupt operations[128]. - The company has not qualified additional suppliers for critical components, which may lead to manufacturing delays and increased expenses[168]. - The company may encounter difficulties in managing its growth, which could disrupt operations and increase net losses[183]. - The reliance on third-party suppliers, including sole source suppliers, exposes the company to risks of supply shortages and price fluctuations[167]. Intellectual Property - As of December 31, 2025, the company holds 13 issued and allowed U.S. patents and 21 international patents, with additional applications pending[62]. - The company acknowledges the uncertainty in obtaining and maintaining valid patents, which may be challenged or not granted, impacting its competitive advantage[211]. - The proprietary AI algorithm used in the SnapShot MSI system is not patent protected, which could affect the company's future development and competitive position[212]. - The company relies on trade secret protection and confidentiality agreements to safeguard proprietary know-how that is not patentable, which is critical for its business[216]. - The company may not be able to effectively enforce its patents or prevent competitors from using similar technologies, which could hinder its business objectives[214]. Cybersecurity and Data Protection - Cyber-attacks pose a significant risk to the company's operations, potentially leading to financial losses and reputational damage[188]. - The company may incur substantial costs related to cyber-attacks, including liability for stolen assets and repairing network infrastructure[191]. - Compliance with data protection laws, including HIPAA and GDPR, is critical, as violations could result in significant fines and operational disruptions[135]. - The company must navigate complex compliance issues arising from varying state and foreign data protection laws, which could complicate operations and increase costs[134]. Human Resources - The company employs 65 full-time employees and plans to hire additional staff in 2026 to support its commercialization and operational goals[66]. - As of December 31, 2025, the company had 65 employees and expects to significantly increase this number, which may complicate management of growth[183]. - The company is at risk of misconduct by employees and contractors, which could lead to regulatory sanctions and reputational harm[140].
Spectral AI(MDAI) - 2025 Q4 - Annual Report